Veda Giri, MD

Veda Giri, MD

Contact Dr. Giri

1025 Walnut Street,
Suite 1015
Medical College Building
Philadelphia, PA 19107

(215) 503-5253
(215) 503-9506 fax

Medical School

Jefferson Medical College - 1997
Pennsylvania State University - 1995

Residency

University of Michigan Medical Center

Fellowship

Fox Chase Cancer Center
University of Michigan Medical Center

Board Certification

Medical Oncology – Recertified 2014
American Board of Internal Medicine – Certified 2002

Hospital Appointment

2014-present, Attending Physician, Thomas Jefferson University Hospitals
2004-2014, Attending Physician, Fox Chase Cancer Center

Research and Clinical Interests

Veda N. Giri, MD is an Associate Professor in Medical Oncology and Cancer Biology at Sidney Kimmel Cancer Center at Thomas Jefferson University.  She is a medical oncologist with a clinical and research interest in inherited cancer risk assessment. Dr. Giri has recently assumed the position of Director of Cancer Risk Assessment and Clinical Cancer Genetics at Thomas Jefferson University, where her role will be to lead an integrated and comprehensive effort in inherited cancer risk assessment and conduct studies focused on genetic evaluation of cancer risk.  Her clinical efforts will be focused on genetic evaluation of inherited risk for GU cancers, specifically prostate, kidney, and upper tract urothelial cancers.  Research studies will encompass genetic characterization of cancer risk using sequencing technologies, molecular signatures, and novel biomarkers to ultimately reduce cancer-related morbidity and mortality.  Her research also has a strong focus in cancer disparities.

 Dr. Giri received her medical degree from Jefferson Medical College, and proceeded to complete her residency in Internal Medicine and fellowship in Hematology-Oncology at the University of Michigan.  She then completed advanced training in molecular cancer genetics at Fox Chase Cancer Center (FCCC).  From 2006-2014, she directed prostate cancer risk assessment at FCCC, developing studies focused on evaluating the role of genetic markers in prostate cancer risk assessment.  Dr. Giri has served on national committees including the National Comprehensive Cancer Network Prostate Cancer Early Detection Panel and NIH PDQ® Cancer Genetics Editorial Board, contributing expertise in cancer risk assessment and prostate cancer genetics.